Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ocugen, Inc. - Common Stock
(NQ:
OCGN
)
0.7452
+0.0205 (+2.83%)
Delayed Quote
Updated: 4:00 PM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ocugen, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Ocugen to Participate in Upcoming November Investor and Industry Conferences
October 29, 2026
From
Ocugen
Via
GlobeNewswire
Next-Gen Biotech: RXRX, OCGN, SNTI, VIVS, ONCO Stocks to Watch
October 28, 2026
Via
AB Newswire
Topics
Artificial Intelligence
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
October 22, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
October 14, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
October 06, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming Scientific Conferences
September 30, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming October Investor and Industry Conferences
September 29, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa
September 25, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
September 01, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming September Investor and Industry Conferences
August 25, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Second Quarter 2026 Financial Results
August 06, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming August Investor Conferences
July 31, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
July 29, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results
July 28, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
July 13, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming July Industry Conferences
July 01, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming June Investor and Industry Conferences
June 02, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
May 14, 2026
Includes Full Exercise of $15.0 million Over-Allotment Option
From
Ocugen
Via
GlobeNewswire
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
May 13, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with First Quarter 2026 Financial Results
May 05, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
May 05, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
May 04, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
April 29, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Present at April 2026 Investor and Industry Conferences
April 23, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
April 01, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
March 24, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
March 23, 2026
From
Ocugen
Via
GlobeNewswire
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 04, 2026
Conference Call and Webcast Today at 8:30 a.m. ET
From
Ocugen
Via
GlobeNewswire
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
March 03, 2026
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
March 02, 2026
From
Ocugen
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
